These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29373687)
1. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687 [TBL] [Abstract][Full Text] [Related]
2. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331 [TBL] [Abstract][Full Text] [Related]
3. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA; JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385 [TBL] [Abstract][Full Text] [Related]
4. First-line antiretroviral drug discontinuations in children. Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529 [TBL] [Abstract][Full Text] [Related]
5. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L; J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274 [TBL] [Abstract][Full Text] [Related]
6. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE; Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460 [TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352 [TBL] [Abstract][Full Text] [Related]
8. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Musiime V; Cook A; Kayiwa J; Zangata D; Nansubuga C; Arach B; Kenny J; Wavamunno P; Komunyena J; Kabamba D; Asiimwe AR; Mirembe G; Abongomera G; Mulenga V; Kekitiinwa A; Kityo C; Walker SA; Klein N; Gibb DM; Antivir Ther; 2014; 19(3):269-76. PubMed ID: 24717427 [TBL] [Abstract][Full Text] [Related]
10. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. Steegen K; Levin L; Ketseoglou I; Bronze M; Papathanasopoulos MA; Carmona S; Stevens W PLoS One; 2014; 9(5):e97067. PubMed ID: 24816790 [TBL] [Abstract][Full Text] [Related]
11. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA; Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944 [TBL] [Abstract][Full Text] [Related]
12. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa. Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis. Adetokunboh OO; Schoonees A; Balogun TA; Wiysonge CS BMC Infect Dis; 2015 Oct; 15():469. PubMed ID: 26502899 [TBL] [Abstract][Full Text] [Related]
14. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449 [TBL] [Abstract][Full Text] [Related]
15. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003 [TBL] [Abstract][Full Text] [Related]
16. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. Tebas P; Zhang J; Hafner R; Tashima K; Shevitz A; Yarasheski K; Berzins B; Owens S; Forand J; Evans S; Murphy R J Antimicrob Chemother; 2009 May; 63(5):998-1005. PubMed ID: 19299471 [TBL] [Abstract][Full Text] [Related]
17. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517 [TBL] [Abstract][Full Text] [Related]
18. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF; HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661 [TBL] [Abstract][Full Text] [Related]
19. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]